Scarica l'app Stockscreener
5.78
1.37%
-0.08
Dopo l'orario di chiusura:
5.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Dimensional Fund Advisors LP Has $1.91 Million Stock Position in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
FDA Fast Track Status Advances Aclaris Lichen Planus Drug - mychesco.com
HC Wainwright Has Pessimistic Outlook of ACRS Q3 Earnings - marketbeat.com
Renaissance Technologies LLC Has $1.89 Million Stake in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance Australia
Aclaris Raises Capital as Drug Pipeline Spending Accelerates - MyChesCo
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - marketbeat.com
Aclaris Therapeutics, Inc. (ACRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade - Zacks Investment Research
Weekly Recap: Q2 loss, runway into 2028 and Fast Track for modzatinib - TradingView
Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - simplywall.st
Aclaris Updates At-The-Market Equity Sales Agreement - theglobeandmail.com
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 6%Here's What Happened - marketbeat.com
US FDA Fast-tracks Aclaris’ Modzatinib for Lichen Planus - The Dermatology Digest
FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com - Investing.com Nigeria
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc (8AT.MU) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Aclaris Therapeutics (NASDAQ:ACRS) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Aclaris Therapeutics (ACRS) Releases Q2 2026 Earnings: Revenue Declines, Losses Narrow - quiverquant.com
FDA grants fast track status to Aclaris’ lichen planus drug - Investing.com
Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) - Yahoo Finance
Aclaris Therapeutics (NASDAQ: ACRS) widens loss as R&D spending accelerates - Stock Titan
Form 8K Aclaris Therapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates - finance.yahoo.com
Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M - marketscreener.com
Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss - marketscreener.com
Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028 - TradingView
ACRS: Higher net loss and R&D spend offset by strong cash reserves and major clinical milestones ahead - TradingView
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com
Aclaris Therapeutics Q2 revenue beats analyst estimates - TradingView
BRIEF-Aclaris Therapeutics Q2 Net Income USD -21.505 Million Vs. IBES Estimate USD -21.3 Million - TradingView
Aclaris Therapeutics 2Q Loss/Shr 15c >ACRS - Moomoo
Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Sets New 1-Year HighStill a Buy? - marketbeat.com
Aclaris Therapeutics Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Aclaris Therapeutics (ACRS) Projected to Post Quarterly Earnings on Thursday - marketbeat.com
Aclaris Therapeutics Inc (ACRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aclaris Therapeutics Inc (ACRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aclaris Therapeutics Inc (ACRS) Cash Flow - TradingKey
Kalehua Capital Management LLC Makes New $6.87 Million Investment in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics Inc (ACRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ACRS|Aclaris Therapeutics Inc|Price:5.380|Chg%:+0.150 - TradingKey
Bollard Group LLC Reduces Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat
Aclaris Therapeutics, Inc. Revenue Breakdown – NASDAQ:ACRS - TradingView
Aclaris Therapeutics Inc (ACRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monashee Investment Management LLC Invests $1.88 Million in Aclaris Therapeutics, Inc. $ACRS - marketbeat.com
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 52-Week HighHere's Why - marketbeat.com
Piper Sandler Reaffirms Their Buy Rating on Aclaris Therapeutics (ACRS) - The Globe and Mail
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Vitiligo Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Dermira, Amgen, Pfizer, Dermavant Sciences, Incyte, TWi Biotechnology, Aclaris - Barchart.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2500 Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 2000 Growth Benchmark - marketscreener.com
Aclaris Therapeutics (ACRS) Declines 1.6% as Shares Approach Support at $4.67Ease of Movement - po-news-eg.net
Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Price to sales forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to book forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Enterprise value to EBIT forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Price to earnings forward of Aclaris Therapeutics, Inc. – DUS:8AT - TradingView
Enterprise value to EBITDA forward of Aclaris Therapeutics, Inc. – NASDAQ:ACRS - TradingView
Aclaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:ACRS) - TradingView
ACRS Forecast — Price Target — Prediction for 2027 - TradingView
ACRS Q1 2026 Earnings: Narrows Loss Per Share as Pre-Revenue Biotech Advances PipelineProfit Cycle Analysis - dars.gov.et
We Think Aclaris Therapeutics (NASDAQ:ACRS) Can Afford To Drive Business Growth - Moomoo
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):